Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Emerging opportunity in a growing, high-value dermatological market

The following is a transcription of the above video, and The Market Online has edited it for clarity . Kane Biotech Inc. (TSXV:KNE) , a Canadian-based biotech company engaged in the development and commercialization of products that prevent and remove microbial biof...

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...

Buzz on the Bullboards: Where volatility meets opportunity

It has been a wild ride for markets on Bay Street and Wall Street this week. Some indices hit lows not seen in nearly a year after a concerning inflation report, only to bounce back the next day. It is reporting season for many companies, and Stockhouse users seem...

Is this stunning 'evidence' that NervGen has the goods?

This could be the signal that tiny NervGen Pharma Corp. (TSX-V:NGEN; OTCQX:NGENF) is destined to be one of the top performing biotech startup stocks this year. It came in a seemingly innocuous podcast interview about the company’s ongoing Phase 1b/2...

Buzz on the Bullboards: Interest rates are still high

Stocks on both sides of the border have wilted in this short trading week. Stocks have since suffered after the Bank of Canada said this week that it would hold its key interest rate at 5 per cent , a 22-year high. The rate pause is in line with economist expectation...

Buzz on the Bullboards: Of interest rates and rebates

Inflation continues to surge out of control to the point where grocery rebates seem to offer little help to struggling Canadians. This holiday-shortened week, markets are adjusting to the U.S. Federal Reserve’s move to raise interest rates. Investors a...

Buzz on the Bullboards: Fail to the chief

It has been an unprecedented week, as focus on major stories related to the financial sector’s struggles and the volatility among crude stocks after OPEC+ said it was slashing output by 1.16 million barrels per day. All eyes were on former President Donald...

Buzz on the Bullboards: Which stocks are turning inertia into momentum?

Markets have stumbled this week, especially tech indices as rising bond yields in the U.S. have had their way with the sector, which is sensitive to higher interest rates. One of the big updates of late, Datametrex AI Ltd. (TSXV:DM) brought investors up to spe...

Numinus Wellness: The mental health business is estimated to grow to $530 billion by 2030

Numinus Wellness is in the business of psychedelic medicine but, more importantly, the mental health business. The mental health business is a sector that will be worth an estimated $530 billion dollars by the year 2030. Numinus has already seen more than a 618% ...

Delivering innovative remote patient monitoring

Welcome to the Market Herald Video Q&A Podcast. I’m Brieanna McCutcheon. Cloud DX is emerging as the partner of choice among the largest global medical technology companies to provide innovative, best-in-class remote patient monitoring (RPM) solu...
1 2 3 4 5 6 7 8 9 10